An assessment of neovascular AMD activity

Article

Looking at an activity socring system to define lesions associated with wet AMD by quantifying their activity to determine the need for treatment.

Key Points

Inactive

Activity scoring system

The proposed ASS is based on the well-known and widely used signs and findings of active CNV:

Apart from FA staining pattern, all of the other assessments are based on the changes in each parameter (same-baseline/increased/decreased) and given a number to define the activity. At the end of the assessment, the numbers are totalled and an activity score is obtained.

Activity scores (AS) can range between 0 and 14. We believe that a CNV lesion with AS of 6–7 or more requires treatment and <6 does not. We are currently compiling a paper to more accurately determine the cut off AS to separate those lesions that need treatment and those that do not.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.